CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Subscribe To Our Newsletter & Stay Updated